Oncology and Therapy
Oncology and Therapy is an international, open access, peer-reviewed, rapid-publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance).
The journal aims to be a key educational tool to help healthcare and industry professionals alike to assess and further understand the place of innovative therapies within the field of oncology by providing comprehensive insights into the most up-to-date research.
The journal is of interest to a broad, global audience of pharmaceutical and healthcare professionals from all disciplines of oncology, and publishes original research, reviews, case reports, and short communications for all aspects of oncology and research around solid tumours, haematological malignancies and cancer-related conditions, including, but not limited to:
• clinical studies (all phases)
• translational research
• molecular diagnosis
• targeted therapy
• personalized medicine
• genetics and genomics
• public health
• patient-reported outcomes
• patient care and management
Articles published in Oncology and Therapy may be accompanied by Plain Language Summaries to assist non-experts (including non-specialists, patients, caregivers and others) in understanding important medical advances.
Moving forward from traditional publishing, Oncology and Therapy offers a range of additional enhanced features designed to increase visibility, readership, and the educational value of the content. Each paper is accompanied by a bulleted Summary slide, giving a time-efficient overview of the content to a wide readership. Authors also have the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are open access and are peer reviewed to the same high standard as the article itself.
Oncology and Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.
The journal follows a single-blind peer review procedure and a minimum of 2 reviewers are required for every manuscript.
Upon acceptance of your article for publication, you will be required to pay the article processing charge of £250/ €340/ $380 per printed page. This will enable you to keep the copyright; you are simply assigning the exclusive right to any commercial use of the article to Springer. Your article will be immediately and permanently available with open access. The journal will consider fee discounts for developing countries and this is decided on a case by case basis
Peer Review Process
Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.
At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication.
For more information about the journal, please contact email@example.com or see the News page for the latest journal offers.
|Previous Title||Print ISSN||Online ISSN|
|Rare Cancers and Therapy||2195-6014||2195-6022|
To view the rest of this content please follow the download PDF link above.